NCT01587716 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 23, 2012

Primary Completion Date

July 30, 2012

Study Completion Date

July 30, 2012

Conditions

Cough

Interventions

DRUG

GSK2339345 (Inhaled) Single Dose

250, 1000 and 2000 microgram (proposed doses)

OTHER

Placebo (Inhaled) Single Dose

Inhaled 0.9% sodium chloride solution

DRUG

GSK2339345 (Inhaled) Repeat Dose

2000 microgram (proposed dose) administered 4 times a day for two consecutive days

OTHER

Placebo (Inhaled) Repeat Dose

Inhaled 0.9% sodium cholride solution

Trial Locations (1)

GSK Investigational Site, London